GOZZINI, ANTONELLA

GOZZINI, ANTONELLA  

Mostra records
Risultati 1 - 20 di 24 (tempo di esecuzione: 0.036 secondi).
Titolo Data di pubblicazione Autore(i) File
ACETYLATION INDUCED BY BUTYRATES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA CAN LEAD TO DIFFENTIATION 2002 A. Gozzini; E. Rovida; A Pratesi; P. Dello Sbarba; P Rossi Ferrini; V. Santini
Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid. 2011 Buchi F; Pastorelli R; Ferrari G; Spinelli E; Gozzini A; Sassolini F; Bosi A; Tombaccini D; Santini V
Butyrates as single drug induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts. 2003 A.GOZZINI; E.ROVIDA; P.DELLO SBARBA; S.GALIMBERTI; V. SANTINI
Complete remission with brentuximab vedotin in a case of primary cutaneous gamma-delta T-cell lymphoma relapsed after allogeneic stem cell transplantation 2021 Lastrucci, Irene; Grandi, Vieri; Gozzini, Antonella; Vannucchi, Margherita; Kovalchuk, Sofya; Santucci, Marco; Pimpinelli, Nicola
EPIGENETIC MODIFICATIONS IN A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE CAUSED BY ADMINISTRATION OF THE HDAC INHIBITOR D1 2004 V. Barbetti; E. Rovida; A. Gozzini; S. Giuntoli; V. Santini; P. Dello Sbarba
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 2014 VALENCIA MARTINEZ, ANA BELEN; Masala, Erico; Rossi, A.; Martino, A.; Sanna, A.; Buchi, Francesca; Canzian, F.; Cilloni, D.; Gaidano, V.; Voso, M. T.; Kosmider, O.; Fontenay, M.; Gozzini, A.; Bosi, Alberto; Santini, Valeria
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. 2014 Valencia A; Masala E; Rossi A; Martino A; Sanna A; Buchi F; Canzian F; Cilloni D; Gaidano V; Voso MT; Kosmider O; Fontenay M; Gozzini A; Bosi A; Santini V.
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. 2016 Bocchia, M; Galimberti, S; Aprile, L; Sicuranza, A; Gozzini, A; Santilli, F; Abruzzese, E; Baratè, C; Scappini, B; Fontanelli, G; Trawinska, Mm; Defina, M; Gozzetti, A; Bosi, A; Petrini, M; Puccetti, L
HDAC INHIBITORS IN COMBINATION WITH HYPOMETHYLATING AGENTS INDUCE SPECIFIC CHROMATIN MODIFICATION AND TRANSCRIPTIONAL ACTIVATION IN CBF/AML CELLS 2005 A. Gozzini; V. Barbetti; E. Rovida; S. Giuntoli; P. Dello Sbarba; V. Santini
In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features 2020 Tusa I.; Cheloni G.; Poteti M.; Silvano A.; Tubita A.; Lombardi Z.; Gozzini A.; Caporale R.; Scappini B.; Dello Sbarba P.; Rovida E.
INCUBATION OF MURINE ERYTHROLEUKEMIA CELLS IN SEVERE HYPOXIA INDUCES MASSIVE APOPTOSIS PARALLELED BY AKT AND ERK5 CLEAVAGE 2004 S. Giuntoli; E. Rovida; V. Barbetti; A. Gozzini; P. Dello Sbarba
Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem-cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo 2011 Alessandrino EP; Angelucci E; Cazzola M; Porta MG; Di Bartolomeo P; Gozzini A; Malcovati L; Pioltelli P; Sica S; Bosi A
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib 2015 Castagnetti, F; Gugliotta, G; Breccia, M; Stagno, F; Iurlo, A; Albano, F; Abruzzese, E; Martino, B; Levato, L; Intermesoli, T; Pregno, P; Rossi, G; Gherlinzoni, F; Leoni, P; Cavazzini, F; Venturi, C; Soverini, S; Testoni, N; Alimena, G; Cavo, M; Martinelli, G; Pane, F; Saglio, G; Rosti, G; Baccarani, M; Bosi, A; Gozzini, A
MAPKS ARE INVOLVED IN THE SURVIVAL AND DIFFERENTIATION OF A T(8;21) ACUTE MYELOID LEUKEMIA CELL LINE AND ARE MODULATED BY THE HDAC INHIBITOR D1 2004 E. Rovida; A. Gozzini; V. Barbetti; S. Giuntoli; V. Santini; P. Dello Sbarba
Mutated ASXL1 and number of somatic mutations as possible indicators of progression to chronic myelomonocytic leukemia of myelodysplastic syndromes with single or multilineage dysplasia 2017 Valencia-Martinez, Ana; Sanna, Alessandro; Masala, Erico; Contini, Elisa; Brogi, Alice; Gozzini, Antonella; Santini, Valeria
Redistribution of H3K27me3 and acetylated histone H4 upon exposure to azacitidine and decitabine results in de-repression of the AML1/ETO target gene IL3. 2014 Buchi F; Masala E; Rossi A; Valencia A; Spinelli E; Sanna A; Gozzini A; Santini V.
Salarin C inhibits maintenance of hypoxia-selected Chronic Myeloid Leukemia progenitor cells 2015 Del Poggetto, E; Tanturli, M; Ben-Califa, N; Gozzini, A; Tusa, I; Cheloni, G; Marzi, I; Cipolleschi, M G; Kashman, Y; Neumann, D; Rovida, E; Dello Sbarba, P
Selective anti-leukaemic activity of low-dose histone deacetylase inhibitor ITF2357 on AML1/ETO-positive cells 2008 Barbetti V, Gozzini A, Rovida E, Morandi A, Spinelli E, Fossati G, Mascagni P, Lübbert M, Dello Sbarba P, Santini V.
Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. 2018 Masala E, Valencia-Martinez A, Pillozzi S, Rondelli T, Brogi A, Sanna A, Gozzini A, Arcangeli A, Dello Sbarba P, Santini V
SPECIFIC DEGRADATION OF THE AML1-ETO/COREPRESSOR COMPLEX BY A NOVEL ORAL HYDROXAMIC ACID DERIVATIVE 2006 V. Barbetti; A. Gozzini; E. Rovida; P. Dello Sbarba; P. Mascagni; V. Santini